Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from The United Laboratories International Holdings ( (HK:3933) ).
The United Laboratories International Holdings Limited, through its wholly owned subsidiary Zhuhai United Bio-Pharmaceutical, operates in the biopharmaceutical sector with a focus on innovative therapies for inflammatory and autoimmune conditions. The company is expanding its R&D pipeline to strengthen its position in advanced biologic treatments and create long-term value for shareholders.
The company announced that China’s National Medical Products Administration has approved its application to conduct a clinical trial for a dupilumab biosimilar injection targeting atopic dermatitis. This milestone advances the group’s presence in high-value biologics, particularly targeted therapies for type 2 inflammatory diseases, and signals continued investment in new products to bolster its market competitiveness and future growth prospects.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a pharmaceutical company based in Hong Kong with operations through subsidiaries such as Zhuhai United Bio-Pharmaceutical Co., Ltd. The group focuses on biopharmaceutical research and development, particularly in treatments for inflammatory and autoimmune diseases, aiming to enhance its competitiveness in the biopharmaceutical industry.
Average Trading Volume: 11,233,325
Technical Sentiment Signal: Hold
Current Market Cap: HK$19.81B
For detailed information about 3933 stock, go to TipRanks’ Stock Analysis page.